Stephens Consulting LLC Has $599,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Stephens Consulting LLC lifted its position in Johnson & Johnson (NYSE:JNJ) by 9.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,143 shares of the company’s stock after buying an additional 349 shares during the quarter. Stephens Consulting LLC’s holdings in Johnson & Johnson were worth $599,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB increased its position in shares of Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after purchasing an additional 52,997 shares during the period. Alpha Financial Partners LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at about $209,000. Brookstone Capital Management raised its position in shares of Johnson & Johnson by 5.5% in the 3rd quarter. Brookstone Capital Management now owns 73,811 shares of the company’s stock valued at $11,962,000 after buying an additional 3,842 shares in the last quarter. Strategic Wealth Partners Ltd. boosted its position in shares of Johnson & Johnson by 2.0% during the 3rd quarter. Strategic Wealth Partners Ltd. now owns 6,401 shares of the company’s stock worth $1,037,000 after acquiring an additional 128 shares in the last quarter. Finally, Brightwater Advisory LLC increased its stake in Johnson & Johnson by 3.4% in the third quarter. Brightwater Advisory LLC now owns 3,713 shares of the company’s stock valued at $602,000 after acquiring an additional 122 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on JNJ shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Citigroup decreased their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Guggenheim increased their target price on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday. Bank of America lowered their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Stock Down 0.8 %

Shares of NYSE JNJ opened at $153.46 on Friday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The stock has a market capitalization of $369.47 billion, a P/E ratio of 23.08, a P/E/G ratio of 2.44 and a beta of 0.52. The company has a 50-day moving average price of $147.49 and a 200-day moving average price of $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.23%. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.